Use of Arterio-venous Fistula as First Choice for Intravenous Drug Administration in Kidney Transplant Recipients

• Conditions: Evaluate the Risks of Using Arteriovenous Fistula as First Choise for Drug Administration

• Registration Number: NCT02874391
• Lead Sponsor: University Hospital, Angers

Brief Summary

Use of arteriovenous fistula for IV drug administration is controversial and often prohibited by nephrologists. However, we have been using this method in our department for years now in order to keep the patients 'veins for other fistulas in the future. The aim of this study is to evaluate our practice and maybe provide a justification for a larger multi-center study given the importance of this subject in patients with chronic renal failure.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-08-17
• Study First Submitted QC: 2016-08-17
• Study First Posted: 2016-08-22
• Study Start: 2016-09
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-19
• Last Update Posted: 2017-01-20
• Primary Completion: 2019-09
• Study Completion: 2019-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Age > 18 years, functional AV fistula, new kidney transplant recipient

Exclusion Criteria

• Prothetic AV fistula, Very recent AV fistula of less than 3 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate the risk of complications of AV fistula	12 months

Trial Locations

Locations (1)

CHU Angers; 🇫🇷 Angers, France